Harriet Kluger, MD

Professor of Medicine (Medical Oncology); Associate Director, Hematology/Oncology Fellowship Program

Physician Biography


Dr. Kluger is a medical oncologist who sees patients with melanoma, renal cell carcinoma and breast cancer. Her research interests focus on developing new drugs and biomarkers predictive of response to these drugs in melanoma and renal cell carcinoma. She participates in a number of clinical trials studying new agents for the treatment of these diseases, both targeting the immune system and the cancer cell. She runs and active research laboratory that studies tumors and cells from patients treated with novel therapies.

Clinical Interests

  • Breast Diseases
  • Medical Oncology
  • Melanoma

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale: Melanoma Program | Prostate and Urologic Cancers Program

General Urology

Medical Oncology: Subset Medical Oncology Faculty

Medical Oncology

Yale Medical Group

Board Certifications

  • Medical Oncology AB of Internal Medicine (2002)

Clinical Trials

Conditions Study Title
Melanoma, skin A Phase I/II, Dose-escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 antibody (Varlilumab) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors (CDX1127-02)
Prostate Genitourinary Cancer Data and Specimen Repository
Unknown Sites Study of Immune System in Patients with Cancer and Blood Disorders
Melanoma, skin Phase I/II study to assess the safety and activity of enhanced TCR transduced autologous T cells against cancer-testis antigens in metastatic melanoma
Bladder, Brain and Nervous System, Breast - Female, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Female Genital, Other Male Genital, Pancreas, Prostate, Rectum, Soft Tissue, Stomach, Thyroid A Phase I, Open-label, dose-escalation study of the safety and pharmacokinetics of MPDL3280A administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors or hematologic malignancies
Melanoma, skin Phase I Dose Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients with Advanced Malignancies
Melanoma, skin A Phase 1, Open label, Dose Finding Study to Assess the Safety and Tolerability of IMCgp100, a Monoclonal T Cell Receptor anti-CD3 scFv Fusion Protein in Patients With Advanced Malignant Melanoma.
Colon, Kidney, Lung, Other Digestive Organ, Rectum, Stomach A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH BEVACIZUMAB AND/OR CHEMOTHERAPY IN PATIENTS WITH ADVANCED SOLID TUMORS
Lung, Melanoma, skin A Phase 2 Study of MK-3475 in patients with metastatic melanoma and non-small cell lung cancer with untreated brain metastases
The Yale School of Medicine Melanoma Patient Registry
Active Surveillance of the Small Renal Mass: An Integrated Biomarker Trial
Melanoma, skin A PHASE 1b STUDY OF THE 4-1BB AGONIST PF-05082566 IN COMBINATION WITH THE PD-1 INHIBITOR MK-3475 IN PATIENTS WITH ADVANCED SOLID TUMORS
Lung, Melanoma, skin A Phase I/II Trial of Evaluating the Combination of MK-3475 and Stereotactic Body Radiotherapy in Patients with Metastatic Melanoma or NSCLC
Melanoma, skin Stand Up To Cancer Consortium - Genomics-Enabled Medicine for Melanoma (G.E.M.M.): Using Molecularly-Guided Therapy for Patients with BRAF wild-type (BRAFwt) Metastatic Melanoma
Other Skin Phase II Study of MK-3475 in Patients with Advanced Merkel Cell Carcinoma
Kidney A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
Soft Tissue Phase 1 Study of Mogamulizumab (KW-0761) in Combination with MEDI4736 and Mogamulizumab in Combination with Tremelimumab in Subjects with Advanced Solid Tumors
Soft Tissue A PHASE I, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF MOXR0916 ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT TO PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
Melanoma, skin A Phase 1, Open-Label, Multicenter, Multi-Dose Escalation Study of CM-24 in Subjects with Selected Advanced or Recurrent Malignancies
A Phase 1, Open Label, Dose Escalation Study of MGA271 (Fc-optimized Humanized Anti-B7-H3-Expressing Neoplasms or Neoplasms Whose Vasculature Expresses B7-H3

Edit this profile

Contact Info

Harriet Kluger, MD
Patient Care Location
Yale Cancer CenterYale-New Haven Hospital
20 York Street, Ste North Pavilion 4

New Haven, CT 06510
Mailing Address
PO Box 208032
New Haven, CT 06520-8028